IRLAB Therapeutics has selected a dopamine receptor agonist candidate called IRL1117 to advance as a Parkinson’s disease treatment, potentially as a longer-lasting alternative to levodopa with lesser side effects.
IRL1117 is designed to be a once-daily oral therapy for the hallmark symptoms of Parkinson’s — tremors, rigidity, and slowness of movements — and the company plans to bring it into a Phase 1 clinical trial in 2024.
Levodopa may slow progression
Clinical trial suggests Parkinson's drug is safe in humans
Hope bioscience is enrolling in 2 clinical trials 
Clinical Trial Update 
